Peplin has U.S. patent granted for novel anti-cancer compounds

Australian biotech Peplin Limited has announced today that the US Patent and Trademark Office had granted Peplin a patent covering the use of its macrocyclic anti-cancer compounds to stimulate the immune system.

Peplin’s Managing Director and CEO, Michael Aldridge said the patent provided Peplin valuable proprietary rights because these anti-cancer compounds have a combined immune system stimulation and direct cytotoxic effect.

These mechanisms of action have been studied extensively in animal models. “Our lead product, PEP005 Topical, directly kills most of the cancer cells and then recruits and activates the local immune system to clean-up the dead cancer cells and kill any remaining live cancer cells.

We believe our drug has very powerful and unique mechanisms of action,” he said. “The way our drug stimulates the body’s immune system and more particularly the local immune response following topical application is an important component of how we are able to induce permanent resolution of skin cancers,” he said.

The grant of this patent extends Peplin’s comprehensive patent protection either granted or under prosecution in the major markets of the world.

These patents cover the use of its compounds against cancer and many other diseases and their immune system stimulating properties.